medigraphic.com
SPANISH

Acta Pediátrica de México

Órgano Oficial del Instituto Nacional de Pediatría
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2012, Number 6

<< Back Next >>

Acta Pediatr Mex 2012; 33 (6)

Tetrahydrobiopterin (Bh4) deficiencies: diagnosis and treatment

Martínez-Pardo M
Full text How to cite this article

Language: Spanish
References: 5
Page: 319-323
PDF size: 83.65 Kb.


Key words:

Tetrahydobiopterin, hyperphenylalaninemia, sapropterin, treatment, diagnosis.

ABSTRACT

Tetrahydrobiopterin (BH4) is an enzyme cofactor of phenylalanine hydroxylase, tyrosine hydroxylase and tryptophan hydroxylase. Three different enzymes affect BH4 synthesis: guanosine triphosphate cyclohydrolase I (GTP CH 1), 6-piruvoil tetrahydropterin synthase (PTPS), sepiapterin reductase (SR) and dihydropteridine reductase (DHPR) affects regeneration. BH4 deficiency causes defects in monoaminergic neurotransmitters synthesis and can be or not associated with hyperphenylalaninemia (HPA). Symptoms often begin in the first months of life with mental retardation, dystonic movements and posture, temperature control disorders, seizures, abnormal posture and tone, salivation and swallowing difficulties. Diagnosis is based on the following tests: pterins in urine, neurotransmitters and pterins in cerebrospinal fluid, reduced enzyme activity (in blood or fibroblasts) and mutational analysis. Treatment should be directed to normalize blood Phe levels and brain neurotransmitters with the administration of BH4 10 mg / kg / d, L-DOPA 10 mg/kg/day and 5-OH-tryptophan, 5 to 6 mg/kg/day. LDOPA should be given with carbidopa in order to inhibit the destruction of the L-dopa by the carboxylase. We describe 3 patients with BH4 deficiency treated at the Ramon y Cajal Hospital. All of them had a good neurological outcome with almost normal mental development.


REFERENCES

  1. Shintaku H. Disorders of tetrahydrobiopterin metabolism and their treatment. Curr Drug Metab 2002;3:123-31.

  2. Longo N. Disorders of biopterin metabolism. J Inherit Metab Dis 2009;32:333-42.

  3. Hyland K. Inherited disorders affecting dopamine and serotonin: critical neurotransmitters derived from aromatic amino acids. J Nutr 2007;137:S1568-72.

  4. Jaggi L, Zurfluh MR, Schuler A. Outcome and long term followup of 36 patients with tetrahydrobiopterin deficiency. Mol Genet Metab 2008;93:295-305.

  5. Schuler A, Kálmánchey R, Barsy P. Deprenyl in the treatment of patients with tetrahydrobiopterin deficiencies. J Inherit Metab Dis 2000;23:229-332.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Acta Pediatr Mex. 2012;33